Close this search box.
Point of Care Diagnostic platform

LumiraDx sells Point of Care Technology Platform to Roche

Published: 15 January 2024

Roche, a global leader in healthcare, has entered into an agreement to acquire select entities within the LumiraDx group, specialising in point-of-care diagnostics and related assets.

The agreement outlines that Roche will pay a base purchase price of USD 295 million (subject to customary closing adjustments). Additionally, an extra payment of up to USD 55 million will be made to cover expenses related to funding the point-of-care diagnostics platform until the acquisition’s completion.

Founded in 2014 and based in the UK, LumiraDx’s diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease.

Point of Care platform

LumiraDx’s Point of Care platform, developed in collaboration with Shore, stands out for its innovative approach: a compact PoC device, microfluidic test strip, standardised workflow for multiple diseases and conditions, and secure digital connectivity.

We were involved in the meter development from the very outset, part of a cross-functional project team with specific responsibility for delivering the strip and reading mechanism, product architecture, and detailed mechanical design. In addition to the instrument design, Shore designed and supplied a range of bespoke equipment to meet testing and production requirements.

Notably, amid the onset of the 2020 pandemic, we worked with LumiraDx to fast-track the platform to detect the SARS-CoV-2 virus, offering a rapid, cost-effective, and scalable solution to the global crisis.

LumiraDx succeeded in creating an instrument that not only rivalled PCR tests in sensitivity but also received FDA authorisation under the emergency use authorisation (EUA) protocol. This breakthrough led to its recognition as the most sensitive antigen test available commercially.

This PoC antigen test emerged as the fastest in the market, finding extensive use in clinics, high street pharmacies, schools, workplaces, live events, and various other global applications.

point of care diagnostics device

Recent News

The image shows a person holding an injection trainer device with the brand name "Shore" clearly visible on it. The device is white with an orange cap and has a clear window showing its internal mechanism. The text on the device reads "Injection Trainer" and specifies "Does not contain needle or medication." The person's left hand is seen removing the transparent cap from the orange tip of the device, indicating the preparation for a simulated injection.

Shore granted US patent for autoinjector trainer design

Shore achieves Carbon Neutral status for 2024

Med-Tech Innovation Expo logo- 5-6 June 2024, NEC, Birmingham, UK

Med-Tech Innovation Expo 2024